Enlivex Advances Phase 2b Trial for Knee Osteoarthritis
The company has randomized 135 patients to test the efficacy of its immunotherapy drug Allocetra.
Updated on Oct. 28, 2026 in Arthritis
Live Poll
Do you believe current medical research is sufficiently prioritizing treatments for aging-related chronic conditions?
Enlivex has randomized 135 participants into its ongoing Phase 2b clinical trial evaluating the immunotherapy drug Allocetra. The study focuses on treating moderate-to-severe primary knee osteoarthritis in patients aged 64 and older.
Why it matters
This trial addresses the growing prevalence of age-related knee osteoarthritis, a condition projected to affect 78 million Americans by 2040. Researchers are testing whether this targeted immunotherapy can provide a new therapeutic option for patients.
The clinical trial is testing Allocetra across 135 enrolled patients out of a total planned cohort of 182 participants aged 64 and older. The study follows the FDA's decision to grant the drug RMAT designation in July 2026.
The players
Enlivex
This biotechnology company is headquartered in Nes-Ziona, Israel, and focuses on the development of immunotherapy treatments.
FDA
The Food and Drug Administration is the United States federal agency responsible for regulating drugs and medical devices.
The details
The trial utilizes a global, multicenter, double-blind, placebo-controlled design with sites across the United States, Denmark, and Poland. Participants began receiving the immunotherapy injections during the randomization process to evaluate its potential impact on knee osteoarthritis.
Timeline
July 2026: FDA granted RMAT designation to Allocetra.
October 28, 2026: Enlivex announced the randomization of 135 patients.
Mid-2027: Expected reporting of topline six-month data.
2040: Projected impact of knee osteoarthritis on 78 million Americans.
Health Landscape
The trial follows the development path established by the FDA's Regenerative Medicine Advanced Therapy (RMAT) designation program to accelerate potential new treatments. This move reflects a broader industry shift toward utilizing accelerated pathways to address the rising clinical burden of age-related joint diseases.
For patients suffering from moderate-to-severe knee osteoarthritis, this trial represents a potential shift toward new, targeted immunotherapy options. Participants and those awaiting future treatments must monitor the study's progress for updates on clinical safety and long-term efficacy.
The takeaway
As the global population ages, developing effective therapies for chronic conditions like osteoarthritis is becoming a primary focus for medical innovation. Patients should consult with their healthcare providers regarding ongoing clinical trial opportunities to gain potential access to emerging treatments.
What happens next
Enlivex is scheduled to report topline six-month data from this clinical trial by mid-2027.
Further reading
Learn more about the latest research and developments in Arthritis.
Source note: This article includes information reported by The Manila times.
Live Poll
Do you believe current medical research is sufficiently prioritizing treatments for aging-related chronic conditions?
